[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342678-105":59,"doc-detail-342678-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","drug-repositioning-for-immunotherapy-in-breast-cancer-using-single-cell-analysis","Drug repositioning for immunotherapy in breast cancer using single-cell analysis","","Drug repositioning explores clinically approved, off-patent compounds to modulate immunotherapy-relevant targets while lowering cost, time, and risk. This study investigates immunomodulatory antimicrobial peptides in breast cancer by comparing malignant versus normal breast epithelial cells using single-cell RNA sequencing, validating chromatin-level findings with ATAC-seq, and assessing protein levels in multiple cancer cell lines. A drug repositioning pipeline prioritizes peptide deregulation to downregulate B2M and SLPI while upregulating PIGR, DEFB1, LTF, CLU, S100A7, and SCGB2A1. Using LINCS L1000, BRD-A06641369, ST-4070043, and BRD-K97926541 are proposed to achieve these effects without disrupting MHC-linked pathways, with additional drug lists compiled for other selected peptides.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/drug-repositioning-for-immunotherapy-in-breast-cancer-using-single-cell-analysis/342678/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/drug-repositioning-for-immunotherapy-in-breast-cancer-using-single-cell-analysis/342678.png","ImageObject",300,407,{"name":92,"@type":93},"Ava Thompson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why use drug repositioning for immunotherapy targets in breast cancer?","Question",{"text":112,"@type":113},"It repurposes existing clinically approved, off-patent drugs with known targets and mechanisms, reducing cost, time, and risk compared with discovering new therapies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the study identify peptide deregulation in breast cancer?",{"text":117,"@type":113},"It analyzes single-cell RNA sequencing data to compare malignant versus non-malignant epithelial cells and validates chromatin-level findings using ATAC-seq, then checks protein levels in breast cancer cell lines.",{"name":119,"@type":110,"acceptedAnswer":120},"Which immunomodulatory peptide changes does the pipeline aim to induce?",{"text":121,"@type":113},"The approach targets downregulation of B2M and SLPI while upregulating PIGR, DEFB1, LTF, CLU, S100A7, and SCGB2A1 in breast cancer epithelial cells.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342678,1790194003,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","npj | systems biology and applications Article  \n\n| Published in partnership with the Systems Biology Institute |  | |  |\n| --- | --- | --- | --- |\n| [https://doi.org/10.1038/s41540-024-00359-z](https://doi.org/10.1038/s41540-024-00359-z) |  |  |  |\n| Drug repositioning for immunotherapy in breast cancer using single-cell analysis\u003Cbr> Check for updates |  |  |  |\n| Elyas Mohammadi1,2 , Samira Dashti3,7, Neda Shaﬁzade3,7, Han Jin 4, Cheng Zhang Mojtaba Tahmoorespur2, Adil Mardinoglu 4,6 & Mohammad Hadi Sekhavati 2  |  | 4, Simon Lam |  5\u003Cbr>, |\n| Immunomodulatory peptides, while exhibiting potential antimicrobial, antifungal, and/or antiviral properties, can play a role in stimulating or suppressing the immune system, especially in pathological conditions like breast cancer (BC) . Thus, deregulation of these peptides may serve as an immunotherapeutic strategy to enhance the immune response. In this meta-analysis, we utilized single-cell RNA sequencing data and known therapeutic peptides to investigate the deregulation of these peptidesin malignant versus normal human breast epithelial cells. We corroborated our ﬁndingsat the chromatin level using ATAC-seq. Additionally, we assessed the protein levels in various BC cell lines. Moreover, our in-house drug repositioning approach was employed to identify potential drugs that could positively impact the relapse-free survival of BC patients. Considering signiﬁcantly deregulated therapeutic peptides and their role in BC pathology, our approach aims to downregulate B2M and SLPI, while upregulating PIGR, DEFB1, LTF, CLU, S100A7, and SCGB2A1 in BC epithelial cells through our drug repositioning pipeline. Leveraging the LINCS L1000 database, we propose BRD-A06641369 for B2M downregulation and ST-4070043 and BRD-K97926541 for SLPI downregulation without negatively affecting the MHC complex as a signiﬁcantly correlated pathway with these two genes. Furthermore, we have compiled a comprehensive list of drugs for the upregulation of other selected immunomodulatory peptides. Employing an immunotherapeutic approach by integrating our drug repositioning pipeline with single-cell analysis, we proposed potential drugs and drug targets to fortify the immune system against BC. |  |  |  |\n| Breast cancer(BC), in general, has low immunogenicity1;however, immune activation can be pivotal in BC prognosis and treatment2. Cancer immunotherapy, also known as immuno-oncology, is a form of cancer treatment that educates, boosts or inhibits the immune system components to prevent, control, or eliminate cancer3. Antimicrobial and immunomodulatory peptides (AMPs) are a part of the innate immune system4. AMPs may directly interact with pathogens and/or malignant cells or indirectly modulate the immune system leading to the elimination of target cells4,5. On the other hand, AMPs that are capable of eliminating pathogens may promote cancer progression6. Therefore, understanding the cancer-speciﬁc response ofAMPsand exploring methods to enhance or suppress it can pave the way for immunotherapy in precision medicine. | To better understand the immunotherapy targets, various techniques are deployed to assess gene expression7 including conventional bulk transcriptomics and single-cell transcriptomics (scRNAseq)8. Bulk transcriptomics measures the average of gene expression across all cells. scRNA-seq deals with gene counts in each cell; hence, it provides the opportunity to categorize and annotate the cell types based on their expression proﬁles. Breast cancer is heterogeneous and also comprises—beyond malignant cells—stromal and immune tumor-associated cells. Although bulk transcriptomics still has its own advantages in cancer immunotherapy8, for precision oncoimmunotherapy scRNA-seq provides higher resolution for both malignant and immune cell proﬁling8,9. |  |  |\n\n1Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden. 2Department of Animal Scie","cbCaidqSZfTHje6O","https://ap.wps.com/l/cbCaidqSZfTHje6O","pdf",2276691,11,"English","# Immunotherapy and peptide deregulation\n## Cancer immunotherapy and AMPs\n## Need for single-cell resolution\n# Study design and objectives\n## Data sources and multi-omics validation\n# Drug repositioning approach\n## Pipeline goals and prioritized peptide targets\n# Results direction\n## Transcriptomics profiles of epithelial cells","[{\"question\":\"Why use drug repositioning for immunotherapy targets in breast cancer?\",\"answer\":\"It repurposes existing clinically approved, off-patent drugs with known targets and mechanisms, reducing cost, time, and risk compared with discovering new therapies.\"},{\"question\":\"How does the study identify peptide deregulation in breast cancer?\",\"answer\":\"It analyzes single-cell RNA sequencing data to compare malignant versus non-malignant epithelial cells and validates chromatin-level findings using ATAC-seq, then checks protein levels in breast cancer cell lines.\"},{\"question\":\"Which immunomodulatory peptide changes does the pipeline aim to induce?\",\"answer\":\"The approach targets downregulation of B2M and SLPI while upregulating PIGR, DEFB1, LTF, CLU, S100A7, and SCGB2A1 in breast cancer epithelial cells.\"}]","Drug repositioning for immunotherapy in breast cancer using single-cell analysis | PDF",1790047692,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b6e264a80d497ea2387c24fa95381b6c.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/45f3daf3a7a88ec72245c647628fc7ff.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8268442f1aaf642c73638d9eaafa1533.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0df339a4ff6ff3f03ad5dac5a0b7e49c.webp",980,1301]